H
Hiroyuki Inoue
Researcher at University of Chicago
Publications - 13
Citations - 542
Hiroyuki Inoue is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer stem cell & Immune system. The author has an hindex of 11, co-authored 13 publications receiving 477 citations. Previous affiliations of Hiroyuki Inoue include Kyushu University.
Papers
More filters
Journal ArticleDOI
Myasthenic crisis and polymyositis induced by one dose of nivolumab
Toshihiro Kimura,Satoshi Fukushima,Azusa Miyashita,Jun Aoi,Masatoshi Jinnin,Takayuki Kosaka,Yukio Ando,Masakazu Matsukawa,Hiroyuki Inoue,Kazuma Kiyotani,Jae-Hyun Park,Yusuke Nakamura,Hironobu Ihn +12 more
TL;DR: T cell receptor repertoire analysis using next‐generation sequencing technologies and identified infiltration of clonally expanded T cell populations in the skeletal muscle after nivolumab treatment, implying a very strong T cell immune response against muscular cells.
Journal ArticleDOI
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.
Hiroyuki Inoue,Jae-Hyun Park,Kazuma Kiyotani,Makda Zewde,Azusa Miyashita,Masatoshi Jinnin,Yukiko Kiniwa,Ryuhei Okuyama,Ryota Tanaka,Yasuhiro Fujisawa,Hiroshi Kato,Akimichi Morita,Jun Asai,Norito Katoh,Kenji Yokota,Masashi Akiyama,Hironobu Ihn,Satoshi Fukushima,Yusuke Nakamura +18 more
TL;DR: It is suggested that melanoma harboring high PD-1 ligands (PD-L1 and PD-L2), GZMA and HLA-A expression may respond preferentially to nivolumab treatment, which can enhance Th1-skewed cellular immunity with oligoclonal expansion of TILs.
Journal ArticleDOI
Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma.
Kazuma Kiyotani,Jae-Hyun Park,Hiroyuki Inoue,Aliya N. Husain,Sope Olugbile,Makda Zewde,Yusuke Nakamura,Wickii T. Vigneswaran +7 more
TL;DR: The results collectively indicate that MPM tumors constitute a diverse heterogeneity in both the genomic landscape and immune micro environment, and that mutation/neoantigen load may affect the immune microenvironment in MPM tissues.
Journal ArticleDOI
Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells
Taigo Kato,Hiroyuki Inoue,Seiya Imoto,Yoshinori Tamada,Takashi Miyamoto,Yo Matsuo,Yusuke Nakamura,Jae-Hyun Park +7 more
TL;DR: The results suggest that both TOPK and MELK are promising molecular targets for kidney cancer treatment and that dual blockade of OTS514 and OTS167 may bring additive anti-tumor effects with low risk of side effects.
Journal ArticleDOI
Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Hiroyuki Inoue,Taigo Kato,Sope Olugbile,Kenji Tamura,Suyoun Chung,Takashi Miyamoto,Yo Matsuo,Ravi Salgia,Yusuke Nakamura,Jae-Hyun Park +9 more
TL;DR: OTS167 appeared to be more effective to CSCs as measured by the sphere formation assay, thus MELK inhibition might become a promising treatment modality for SCLC.